Teva Drug Patent Portfolio
Teva owns 3 orange book drugs protected by 35 US patents Given below is the list of Teva's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11311488 | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof | 10 Jun, 2041 | Active |
| US11179386 | Analogs of deutetrabenazine, their preparation and use | 15 Sep, 2038 | Active |
| US11813232 | Analogs of deutetrabenazine, their preparation and use | 15 Sep, 2038 | Active |
| US11179386 | Analogs of deutetrabenazine, their preparation and use | 15 Mar, 2038 | Active |
| US11813232 | Analogs of deutetrabenazine, their preparation and use | 15 Mar, 2038 | Active |
| US10959996 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
| US11357772 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
| US11446291 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
| US11564917 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
| US11648244 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
| US12016858 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
| US10959996 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
| US11357772 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
| US11446291 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
| US11564917 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
| US11648244 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
| US12016858 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
| US9550780 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Mar, 2034 | Active |
| US9550780 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Sep, 2033 | Active |
| US9023897 | Biodegradable drug delivery compositions | 05 Apr, 2033 | Active |
| US8524733 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | 03 Oct, 2031 | Active |
| US8524733 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | 03 Apr, 2031 | Active |
| US8221778 | Drug-containing implants and methods of use thereof | 12 Nov, 2027 | Active |
| US8741327 | Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant | 12 Nov, 2027 | Active |
| US7815942 | Rasagiline formulations of improved content uniformity | 27 Aug, 2027 | Active |
| US7572834 | Rasagiline formulations and processes for their preparation | 05 Dec, 2026 | Active |
| US10736965 | Risperidone biodegradable implant | 12 Jan, 2025 | Active |
| US8802127 | Risperidone-containing PLA:PGA implants and methods of use thereof | 12 Jan, 2025 | Active |
| US9439905 | Risperidone-containing implants and methods of use thereof | 12 Jan, 2025 | Active |
| US9717799 | Drug-containing implants and methods of use thereof | 12 Jan, 2025 | Active |
| US9895447 | Drug-containing PLA implants and methods of use thereof | 12 Jan, 2025 | Active |
| US9925268 | Drug-containing implants and methods of use thereof | 12 Jan, 2025 | Active |
| US5453446 | Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. | 07 Feb, 2017 | Expired |
| US6126968 | Stable compositions containing N-propargyl-1-aminoindan | 18 Sep, 2016 | Expired |
| US5532415 | R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof | 02 Jul, 2013 | Expired |
Latest Legal Activities on Teva's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Teva.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2024 | US9550780 |
| Surcharge for Late Payment, Large Entity | 17 Apr, 2024 | US10736965 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Apr, 2024 | US10736965 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Apr, 2024 | US10736965 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Feb, 2024 | US9439905 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 03 Jan, 2024 | US8221778 |
| Mail Patent eGrant Notification | 14 Nov, 2023 | US11813232 |
| Recordation of Patent eGrant | 14 Nov, 2023 | US11813232 |
| Patent eGrant Notification | 14 Nov, 2023 | US11813232 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 14 Nov, 2023 | US11813232 |
|
Email Notification
Critical
| 14 Nov, 2023 | US11813232 |
|
Recordation of Patent Grant Mailed
Critical
| 14 Nov, 2023 | US11813232 |
|
Email Notification
Critical
| 27 Oct, 2023 | US11813232 |
|
Issue Notification Mailed
Critical
| 25 Oct, 2023 | US11813232 |
|
Application Is Considered Ready for Issue
Critical
| 16 Oct, 2023 | US11813232 |
Teva's Drug Patent Litigations
Teva's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 08, 2021, against patent number US8524733. The petitioner Apotex Inc., challenged the validity of this patent, with Auspex Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Teva's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8524733 | September, 2021 |
Terminated-Denied
(09 Mar, 2022)
| Auspex Pharmaceuticals, Inc. | Apotex Inc. |
Teva Drug Patents' Oppositions Filed in EPO
Teva drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 13, 2017, by Generics (U.K.) Limited. This opposition was filed on patent number EP06720975A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP06720975A | Feb, 2017 | Generics (U.K.) Limited | Patent maintained as amended |
Teva's Family Patents
Teva drugs have patent protection in a total of 35 countries. It's US patent count contributes only to 33.5% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Teva Drug List
Given below is the complete list of Teva's drugs and the patents protecting them.
1. Austedo Xr
Austedo Xr is protected by 21 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11311488 | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
10 Jun, 2041
(16 years from now)
| Active |
| US11179386
(Pediatric)
| Analogs of deutetrabenazine, their preparation and use |
15 Sep, 2038
(13 years from now)
| Active |
| US11813232
(Pediatric)
| Analogs of deutetrabenazine, their preparation and use |
15 Sep, 2038
(13 years from now)
| Active |
| US11179386 | Analogs of deutetrabenazine, their preparation and use |
15 Mar, 2038
(13 years from now)
| Active |
| US11813232 | Analogs of deutetrabenazine, their preparation and use |
15 Mar, 2038
(13 years from now)
| Active |
| US10959996
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
| US11357772
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
| US11446291
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
| US11564917
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
| US11648244
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
| US12016858
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
| US10959996 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
| US11357772 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
| US11446291 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
| US11564917 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
| US11648244 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
| US12016858 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
| US9550780
(Pediatric)
| Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Mar, 2034
(9 years from now)
| Active |
| US9550780 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Sep, 2033
(8 years from now)
| Active |
| US8524733
(Pediatric)
| Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
03 Oct, 2031
(6 years from now)
| Active |
| US8524733 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
03 Apr, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Austedo Xr's drug page
2. Azilect
Azilect is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7815942 | Rasagiline formulations of improved content uniformity |
27 Aug, 2027
(2 years from now)
| Active |
| US7572834 | Rasagiline formulations and processes for their preparation |
05 Dec, 2026
(2 years from now)
| Active |
| US5453446 | Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. |
07 Feb, 2017
(7 years ago)
| Expired |
| US6126968 | Stable compositions containing N-propargyl-1-aminoindan |
18 Sep, 2016
(8 years ago)
| Expired |
| US5532415 | R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof |
02 Jul, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Azilect's drug page
3. Uzedy
Uzedy is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9023897 | Biodegradable drug delivery compositions |
05 Apr, 2033
(8 years from now)
| Active |
| US8221778 | Drug-containing implants and methods of use thereof |
12 Nov, 2027
(3 years from now)
| Active |
| US8741327 | Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant |
12 Nov, 2027
(3 years from now)
| Active |
| US10736965 | Risperidone biodegradable implant |
12 Jan, 2025
(2 months from now)
| Active |
| US8802127 | Risperidone-containing PLA:PGA implants and methods of use thereof |
12 Jan, 2025
(2 months from now)
| Active |
| US9439905 | Risperidone-containing implants and methods of use thereof |
12 Jan, 2025
(2 months from now)
| Active |
| US9717799 | Drug-containing implants and methods of use thereof |
12 Jan, 2025
(2 months from now)
| Active |
| US9895447 | Drug-containing PLA implants and methods of use thereof |
12 Jan, 2025
(2 months from now)
| Active |
| US9925268 | Drug-containing implants and methods of use thereof |
12 Jan, 2025
(2 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Uzedy's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List